首页> 外文期刊>Journal of the Chemical Society, Perkin Transactions 1 >Design and preparation of serine–threonine protein phosphatase inhibitors based upon the nodularin and microcystin toxin structures. Part 3
【24h】

Design and preparation of serine–threonine protein phosphatase inhibitors based upon the nodularin and microcystin toxin structures. Part 3

机译:基于结节蛋白和微囊藻毒素的结构设计和制备丝氨酸-苏氨酸蛋白磷酸酶抑制剂。第三部分

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Nodularin and microcystins are complex natural cyclic isopeptidic hepatotoxins that serve as subnanomolarninhibitors of the eukaryotic serine–threonine protein phosphatases PP1 and PP2A, enzymes that are intimatelyninvolved in controlling cellular metabolism. Previously we described a solution-phase synthesis of stripped-downnnodularin analogues; cyclo[-β-Ala-(R)-Glu-α-OMe-γ-Sar-(R)-Asp-α-OMe-β-(S)-Phe-] 3 and cyclo[-(3R)-3-hydroxymethyl-nβ-Ala-(R)-Glu-α-OMe-γ-Sar-(R)-Asp-α-OMe-β-(S)-Phe-] 5. The synthetic strategy was designed to allownpost-macrocyclisation elaboration. Here we examine alternative methods for introducing diversity and achievingnmacrolactamisation and compare the relative efficiency of solution- vs. solid-phase peptide syntheses of the macrocycles.nSyntheses and the biological activities of the macrocycles cyclo{-[(2R)-α-4-benzylpiperidinylamido-Asp]-β-n[(R)-Glu]-γ-Sar-[(R)-Asp]-β-(S)-Phe-} 29 and cyclo{-(2S)-Phe-[(2R)-α-4-benzylpiperidinylamido-Asp]-(R)-Glu-γ-n(S)-Pro-β-(R)-Asp-} 65 are compared. Both compounds contain sufficient side-chain functionality to interact with anhydrophobic groove at the enzyme active site. The proline containing analogues 30, 31 (R3 = CH3) where sarcosine isnreplaced in macrocycles 3 and 4, were also synthesised in order to correlate conformational properties with biologicalnactivity. In accord with predictions macrocycles 29 and 65 were found to be weak inhibitors of PP1 with IC50 2.9 andn2.7 mM respectively.
机译:结节菌素和微囊藻毒素是复杂的天然环状异肽肝毒素,可作为真核丝氨酸-苏氨酸蛋白磷酸酶PP1和PP2A的亚纳米糖抑制剂,这些酶与控制细胞代谢密切相关。先前,我们描述了脱皮的戊二醛类似物的溶液相合成。环[-β-Ala-(R)-Glu-α-OMe-γ-Sar-(R)-Asp-α-OMe-β-(S)-Phe-] 3和环[-(3R)-3 -羟甲基-nβ-Ala-(R)-Glu-α-OMe-γ-Sar-(R)-Asp-α-OMe-β-(S)-Phe-] 5.设计合成策略是为了允许-大环化的详细说明。在这里,我们研究了引入多样性并实现甲基内酰胺化的替代方法,并比较了大环化合物的固相和固相肽合成的相对效率。n合成和大环化合物的生物活性-Asp]-β-n[(R)-Glu]-γ-Sar-[[R)-Asp]-β-(S)-Phe-} 29和环{-(2S)-Phe-[(2R比较)-α-4-苄基哌啶基氨基-Asp]-(R)-Glu-γ-n(S)-Pro-β-(R)-Asp-} 65。两种化合物均具有足够的侧链官能度,可与酶活性位点的疏水沟相互作用。还合成了含有脯氨酸类似物30、31(R3 = CH3)的脯氨酸,其中肌氨酸在大环3和4中被取代,以使构象性质与生物活性相关联。与预测一致,发现大环化合物29和65是PP1的弱抑制剂,IC50分别为2.9和n2.7 mM。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号